Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma

沙利度胺类药物（称为IMiD）是多发性骨髓瘤（一种常见的无法治愈的血癌）的基本治疗方法。我们发现IMiDs破坏了骨髓瘤细胞用来“读取”自身DNA中致癌基因的蛋白质。因此，我们将研究这些“基因阅读器”在骨髓瘤细胞（包括患者样本）中的破坏有多重要。这将建立未来的研究，针对“基因阅读器”使用IMiDs与其他靶向药物在临床试验中结合。

Thalidomide-like drugs (called IMiDs) are an essential treatment for multiple myeloma, a common incurable blood cancer. We have discovered that IMiDs destroy proteins that myeloma cells use to ‘read’ cancer-causing genes in their own DNA. We will therefore investigate how important the destruction of these ‘gene readers’ is in myeloma cells, including patient samples. This will set up future studies targeting ‘gene readers’ using IMiDs in combination with other targeted drugs in clinical trials.